Introduction
Chest pain of recent onset accounts for over 500 000 outpatient appointments per year in the UK. 1 Most hospitals offer a Rapid Access Chest Pain Clinic (RACPC) service to evaluate such patients. Patients with suspected stable angina (SA) without known coronary artery disease (CAD) are first assessed clinically for probability of CAD followed by further diagnostic testing when calculated pre-test probability of CAD (.10%). 2 Both the recent European Society of Cardiology (ESC) and American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend Exercise ECG (ExECG) as the first line investigation in patients who can exercise and who have no resting ECG abnormalities. 3, 4 These guidelines were mainly based on two randomized studies comparing ExECG with stress single-photon-emission-computerized tomography (SPECT). 5, 6 Both these trials showed that ExECG was more cost-efficient than SPECT in the management of patients with suspected SA without known CAD. The National Institute for Health and Clinical Excellence (NICE) guideline, on the other hand, does not advocate ExECG for the assessment of CAD. 2 However, despite NICE guidelines, ExECG continues to be used as first line investigation in UK 7 probably because of its perceived higher feasibility, ability to obtain physiological exercise data, and superior cost profile compared with other non-invasive tests. Stress echocardiography is an alternative technique that can be performed using exercise. Exercise stress echocardiography (ESE) has been found to be more accurate than ExECG for the detection of CAD. 8 This is both due to the fact that, in the ischaemic cascade, wall motion abnormalities can occur prior to ECG changes and also because ECG changes may occur without the presence of flow-limiting CAD. Recent, technological advances such as tissue harmonic imaging, digital image acquisition, and the advent of trans-pulmonary echo-contrast agents have all led to improved image quality, feasibility and reproducibility of SE. 9, 10 Although there have been several studies demonstrating superior cost-efficacy of stress echocardiography over ExECG in patients with SA, these were all retrospective, in patients with both suspected and known CAD and in one study both exercise and dobutamine stress echocardiography were employed. 11, 12 There is, therefore, no randomized prospective study comparing ESE and Ex-ECG in patients presenting for the first time with recent onset suspected stable angina-a population of particular clinical and economic interest as it comprises the majority of patients seen in RACPC. In particular, no previous randomized study has been performed in a real clinical setting comparing the use of these two techniques in patients with anything but a very low pre-test probability. We hypothesized that contemporary ESE is feasible, more accurate, and thus conveys a cost-saving benefit compared with ExECG for the assessment of CAD when used as the initial test in patients with suspected SA, with no resting ECG changes and without known CAD, who can exercise.
Methods

Study design
Consecutive consenting patients, who were seen in the RACPC of our local hospital from February 2013 to March 2014, were randomized to undergo either an ExECG or an ESE on the day of their clinic attendance. Patients included in the study were patients with no previous history of CAD, who were deemed able to exercise on a treadmill, had a normal resting ECG at baseline, a pre-test probability of CAD of .10% (according to NICE guidelines), 2 and who were able to consent. As the study received ethical approval and was performed in the UK, we opted to use the NICE algorithm for pre-test probability to best reflect current clinical practice.
Patients excluded from the study were those with unstable angina, previous history of CAD [myocardial infarction (MI), coronary revascularization, or CAD on coronary angiography], and those with pre-test probability of CAD ,10%.
The pre-test probability of CAD was calculated for each individual patient based on the description of the presenting symptoms and the presence of established risk factors. 13 Patients were classified into low (10 -30%), intermediate (30 -60%), and high (.60%) pre-test probability of CAD. Finally, patients who were deemed unable to give informed consent either due to the presence of comorbidities (e.g. memory impairment) or due to insurmountable language barriers were not approached for consent. The primary outcome of the study was the cost to diagnosis of CAD as defined below and the secondary outcome was the rate of detection of obstructive CAD following a positive initial study.
Consenting patients were randomized using a random number generator algorithm incorporated into a Microsoft Access Database. Basic demographic information was collected on all patients.
Exercise testing
Patients in both arms of the study underwent treadmill exercise using the standard Bruce protocol according to standard clinical practice. The endpoints for the tests have been well established in previous studies 14, 15 and are described in full detail in Appendix 2.
Exercise ECG
All ExECGs were performed and interpreted by experienced cardiac physiologists and the RACPC healthcare professional (Cardiac Specialist Nurse or cardiology middle grade doctor) as per standard clinical practice. The reporters were blinded as to the patient's participation in the study. Tests were reported as negative, positive, or inconclusive for ischaemia according to pre-determined parameters (Appendix 2).
Exercise stress echocardiography
A resting two-dimensional echocardiogram was performed in the lateral decubitus position. Digital images, with tissue harmonic imaging, of the Left Ventricle (LV) were obtained in the parasternal long-axis, shortaxis, and apical, four-, two-, and three-chamber views using an IE33 echocardiography system with an S5 probe (Philips, Best, the Netherlands). ESE images were acquired immediately (within 90 s) after peak exercise. Immediate post-exercise images with the best endocardial definition were selected and displayed alongside the corresponding baseline images. In technically difficult patients (when two or more segments were not adequately visualized at rest or during deep breathing), intravenous contrast (Sonovue, Bracco, Milan, Italy) was used to enhance endocardial border definition. Bolus injections of 0.3 -0.5 mL were administered through a peripheral cannula followed by a flush with 0.9% NaCl solution. The ESE was performed by multiple operators as per our clinical practice.
Image analysis
Online digital images were interpreted qualitatively for the presence, extent, and location of regional wall motion abnormalities (RWMA) by the consultant lead (R.S.) as per routine clinical practice. The reviewer thus had no knowledge that images are from a patient in the study. Systolic wall thickening and endocardial wall motion were assessed according to a four-point score (1: Normal; 2: Hypokinetic; 3: Akinetic; 4: Dyskinetic motion) using a 17-segment left-ventricle LV model. The stress echocardiogram was considered negative if all segments were normal at baseline and peak stress having achieved 85% of age-predicted target heart rate at a workload of at least 7Mets. 16 Patients with evidence of WMA at rest or development of regional WMA at peak stress were deemed to have a positive stress echocardiogram. Patients with uninterpretable images or patients that failed to achieve the target heart rate were considered to have an inconclusive test.
Downstream testing
In accordance with the study design, patients with an inconclusive ExECG were offered an ESE or, in cases when the target heart rate was not achieved through exercise, a dobutamine stress echocardiogram (DSE). Patients with an inconclusive ESE underwent further investigations. Patients with a positive ExECG or ESE were offered invasive coronary angiography (CA).
Coronary angiography
Standard techniques were used for performing the angiogram. Images were analysed using a visual quantitative scoring system, with CAD defined as .50% luminal diameter narrowing in one or more epicardial coronary arteries or their major branches. The cut-off value of 50% was used as it has been previously shown to be prognostic. 17 
Cost to diagnosis of CAD
The cost to diagnosis of CAD was performed using data from the NHS resource tariff of 2012 -13. 18 Resource use data were collected for all patients on an intention-to-treat basis. We took into account cases where investigations were performed as well as cases where investigations were requested but were not performed due to patients not attending. Cost to diagnosis was defined as the sum of all investigations performed up to and including the point when diagnosis or presumed absence of CAD was deemed established. These included a diagnostic CA, a negative functional test, or a decision not to proceed with any further tests.
Follow-up
Data were collected by means of a postal questionnaire at 1 year after the clinic appointment (Appendix 1). Patients consented to be approached for follow-up as part of the study protocol. Data were collected on MI, death, and unplanned revascularization. Cardiac death was defined as death associated with known or suspected MI, lifethreatening cardiac arrhythmia (VT or VF) or heart failure based on clinical assessment, serum cardiac markers (Troponin I), ECG, or cause of death listed on national registry. Non-fatal MI was defined according to established criteria. 19 Coronary revascularization was defined as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
Patients who did not respond to the postal questionnaire were contacted via telephone. In cases where patients could not be contacted directly, an electronic search of the hospital records and the NHS registry was performed. Follow-up assessment was performed by a research nurse, who was blinded to the study group. Follow-up time was calculated from the day of the initial test to either the date of an event or the date follow-up contact or database search was performed.
Statistical analysis
A power calculation performed by an independent statistician, based on the results of a previous retrospective study, suggested that 186 patients would have to be randomized into each study arm for the study to show a difference in cost and 190 patients to show a difference in positive predictive value with a 5% significance level and 80% power. The number of patients in the study was selected based on these power calculations.
Continuous variables are shown as mean + SD. 
Ethics
The study received ethics permission from our local ethics board and informed consent was obtained in writing from all patients.
Results
We recruited 385 patients in the study over a period from February 2013 to March 2014. A total of 194 patients and 191 patients were randomized into the ExECG and ESE groups, respectively. All of the patients underwent testing on the day of their clinic appointment or the next working day. There were no significant differences in the pre-test probability of CAD, age, gender, and cardiac risk factors between the two groups ( Table 1) . The flow of patients through the study is illustrated in Figure 1 . Patients with an inconclusive ExECG were offered either ESE or DSE depending on their ability to reach target heart rate on exercise, as per standard clinical practice in our department. In total, 65 patients were referred for ESE and seven were referred for DSE. Out of a total of 72 patients, five patients were offered subsequent CA.
Exercise ECG
Stress echocardiography
Out of a total of 191 patients randomized into ESE, 181 (94.8%) were deemed to have a negative test, nine (4.7%) to have a positive test, and only on one occasion (0.5%) was the ESE deemed to be inconclusive. This was on a patient who was on treatment with beta-blockers for hypertension and was thus unable to reach target heart rate on exercise. The patient underwent a second ESE off beta-blockers after 48 h, which was negative. All nine patients with a positive test were offered CA.
Probability of CAD
The proportion of patients classified as having a low (40 vs. 41%), intermediate (38 vs. 31%), and high (22 vs.28%) probability of CAD pre-test was comparable between the ExECG and the ESE groups, respectively (P ¼ 0.3). The proportion of patients reclassified into low, intermediate, and high probability of CAD after the initial investigation is shown in Table 2 . Post-initial test, significantly more patients were classified as having a low post-test probability (94.8 vs.55.7%, P , 0.01) in the ESE group than the ExECG group. Similarly, significantly fewer patients were classified as having intermediate post-test probability in the ESE group than in the Ex-ECG group (0.5 vs. 37.1%, P , 0.01). Overall, following ESE, definitive classification to low and high probability of CAD was achieved in significantly more patients compared with ExECG (99.5 vs. 62.9%, P , 0.01). The pre-and post-test CAD probability percentages of patients are illustrated in Figure 2 .
Detection of obstructive CAD
All of the nine patients referred for CA on the basis of a positive ESE were found to have obstructive CAD on angiography compared with 9 out of 14 patients who were referred on the basis of a positive ExECG (P ¼ 0.04).
Cost analysis
The total use of resources and the cost per unit for the two groups is shown in Table 3 . As a result of the much fewer downstream investigations required in the ESE group, the mean cost to either confirm or refute the diagnosis of CAD was significantly lower for the ESE group (£266) compared with the ExECG group (£327) (P ¼ 0.005) despite the higher initial cost. Similar cost savings are demonstrated when using the Medicare Costs in the USA ($366) vs. ($420) per patient in the ESE vs. ExECG group, respectively. 21 A cost calculation using the same methodology for USA and Belgium (personal communication) is shown in Table 4 .
Follow-up
Of the 385 patients randomized, 303 patients were contacted by postal questionnaire or by phone. In the remaining 82 patients, data on death, MI, and unplanned revascularization were collected by contacting the patient's primary physician and by searching the electronic patient's records as per study design. Follow-up was performed over a mean follow-up period of 21 + 5 months.
There was only one death recorded in the study population. This occurred in a patient who was discharged on the basis of a negative stress echo. The patient subsequently was re-admitted for urgent non-cardiac surgery. He was discharged from hospital and later on died at home. A post-mortem was performed at which there was no evidence of MI or acute coronary thrombosis. There was, however, evidence of coronary atherosclerosis and the coroner listed the cause of death as coronary artery disease. For the purpose of the study, therefore, this is considered a cardiac death. No MIs or unplanned revascularization procedures were recorded in patients who were initially revascularized following a positive test. In the group of patients initially discharged following a negative ESE, one patient was re-admitted with unstable angina 22 months after his initial discharge and underwent PCI.
Discussion
The present study is, to our knowledge, the first prospective randomized trial, performed under real-world conditions, comparing the relative value of ESE and ExECG in patients who presented with new suspected stable angina, with no previous history of CAD, without resting ECG abnormalities, and who were able to exercise. This is a typical population (pre-test median probability of CAD: 34% + 23), which according to both AHA/ACC and ESC guidelines would undergo ExECG. 3, 4 This study demonstrated that, in this population, an initial investigation with ESE conveyed a significant cost-benefit compared with an initial investigation with ExECG. This is because, ESE re-stratified a significantly higher proportion of patients (.90%) as low risk compared with 55% in the ExECG arm, with no difference in event rates during 21 months of follow-up between the two groups. Thus, 50% of patients in the ExECG arm underwent further investigation compared with ,10% in ESE group. At the same time, all the patients who were classified as high risk of CAD after a positive ESE were found to have obstructive CAD compared with only 64% of those classified as high risk following a positive ExECG. Thus, ESE was more accurate than ExECG for the prediction of obstructive CAD. Furthermore, no patients with a low pre-test risk were upgraded into high or intermediate risk following 
Comparison with previous studies
A previous study comparing ESE vs. ExECG had indicated that ESE was more accurate than ExECG for the detection of CAD. 22 The same authors then retrospectively evaluated a large population comparing initial ESE vs. ExECG and concluded that the former is more cost-effective than the latter for the detection and risk stratification for CAD. 8 Similar to our study, ESE identified more patients as low risk (51 vs. 24%, P , 0.001), and fewer as intermediate (27 vs. 51%, P , 0.001) vs. ExECG. However, 25% of the study population had a history of previous CAD. A recent retrospective observational study also indicated similar findings in the population that the present study addressed. 12 An initial strategy with SE was significantly superior compared to ExECG for predicting post-test probability of CAD, classified more patients as low risk of having CAD and fewer patients with intermediate probability of post-test CAD compared to ExECG. The combined effect translated into a superior cost profile for SE. However, besides the study being retrospective and observational, the comparison was between ExECG vs. SE, including patients undergoing pharmacological stressing with dobutamine. The study was not therefore a true comparison of similar risk populations. Moreover, dobutamine stress echocardiography does not provide comparable physiological data to ExECG. The first head to head prospective study of this population comparing, Ex-ECG with another form of exercise functional imaging, used exercise and single-photon-emission-tomography (SPECT) in women. 6 Despite significantly higher intermediate-high-risk post-tests and resultant more downstream testing in the ExECG group, ExECG resulted in 48% lower cost than ExSPECT with no difference in outcome. This was mainly because of a significantly higher initial testing cost with ExSPECT. In the present study in addition to lower initial ESE cost, compared with ExSPECT, only 5% of patients in the ESE group underwent further testing compared with 15% in the SPECT arm in the previous study. This difference could also account for the better cost-profile with ESE. An important factor in the achievement of high rates of diagnostic testing in the ESE arm is the ability to obtain high quality images with the advent of tissue harmonic imaging and contrast-enhanced echocardiography in recent years. These resulted not only in high feasibility of obtaining diagnostic images but also translated into improved diagnostic accuracy of SE. 10, 23 Thus, despite high usage of contrast-enhanced SE the cost of ESE strategy was superior to Ex-ECG and this is likely because of the increased accuracy of the test and greater diagnostic certainty which reduced unnecessary downstream cost. This was also previously demonstrated in another prospective randomized trial comparing ESE with ExECG in patients with suspected acute coronary syndrome. 15 
Clinical implications
Initial testing with ExECG is recommended both by AHA/ACC and ESC guidelines in patients with suspected angina and no prior history of CAD who can exercise and have no resting ECG changes. The ESC guidelines, however, advocated use of ExECG in patients with a pretest probability of 15-65%. These guidelines are mainly based on a couple of previous randomized studies comparing ExECG to SPECT. 5, 6 ExECG was found to be more cost-effective in this low risk population. The present study clearly showed that ESE was more cost-efficient than ExECG in a population where the median pre-test probability of CAD was 34%. However, the rate of positive stress test was only 6% with an event rate of around 0.5% over 1.8 years. While one can argue against any further testing in this low-risk population, correct identification and management instituted in the 5% of patients with confirmed CAD may have altered the overall outcome and cannot be ignored. This study also highlights the gross overestimation of CAD risk by the existing pre-test probability algorithms. One option would be to design new risk-stratification algorithms to determine whether further testing is warranted. However, in this lowrisk population, the ideal test must be one which follows the least potential to harm-ALARA (As Low as Reasonably Achievable) principle while at the same time being relatively accurate and cost-effective. Ex-ECG has been advocated as such a test in terms of safety combined with the physiological data that it provides that helps to effectively risk stratify patients. ESE which has a similar safety profile to ExECG can assess myocardial wall thickening-a more accurate marker of ischaemia than ECG-and like ExECG provide physiological exercise data for additional risk stratification. ESE has been shown to be superior to ExECG both for the detection of CAD and risk stratification in several studies both in patients with known CAD and without known CAD. 8, 11, 12, 22, 24 Retrospective observational studies indicated superior cost-profile of SE vs. ExECG in patients with and without previous history of CAD. 11, 12 The present randomized, prospective study confirms both the superior rate of detection of obstructive CAD and cost-benefit of ESE compared with ExECG. Computerized tomographic coronary angiography (CTCA) has been advocated by NICE particularly in the group of patients with low pre-test probability. However, both PROMISE and SCOT HEART, which are randomized trials comparing management strategies based on CTCA vs. functional testing failed to show superiority of CTCA with regards to outcome. 7, 25 The failure of CTCA to improve outcome compared with functional testing, together with safety concerns arising from the use of ionizing radiation, makes CTCA a rather unattractive technique in the very low-risk cohort that the present study addressed. A similar safety concern with SPECT combined with its failure to demonstrate cost-advantage over ExECG also precludes the use of this test in this population. 5, 6 Echocardiography matches ECG in terms of their excellent safety profile and ESE matches ExECG in terms of obtaining exercise physiology data but the echocardiography component of ESE provides superior diagnostic information compared with the ECG component of ExECG which translated into improved cost-savings (19%) in the present study.
Study limitations
It is evident from the study that the pre-test risk of patients is an overestimate. This is in fact recognized by the NICE guideline, 2 which suggests that the algorithm used to calculate risk may overestimate risk in the primary care setting. As a result of the overall low risk, the number of events is small. The study may, therefore, not be powered to show a difference in outcome.
A single reader interpreted all ESE images. There is always a degree of intra-observer variability and ideally, images should have been assessed by more than one blinded expert. However, the echocardiography images were acquired by multiple operators and the final report was confirmed by the expert reader as per normal clinical practice. Thus the study reflected a real world clinical practice.
The costs reported in this study as well as the algorithm used for risk stratification of patients, are based on UK data so may not apply to other healthcare systems. However, similar cost analysis based on Medicare cost in USA and based on personal communication from Belgium showed ESE to be cheaper to ExECG for diagnosis of CAD, in these countries. The cost analysis is based on cost to diagnosis of CAD rather than additional downstream cost related to outcome. Hence, we avoided using the term 'cost-effectiveness'. However, we have been consistent in using the same approach with our previous studies, 12, 15 as using this methodology makes it easier to reproduce the study in other real clinical settings/ healthcare models.
Conclusion
Initial ESE strategy was superior to initial ExECG for the prediction of obstructive CAD and provided significant cost saving in patients with no previous history of CAD who present with suspected stable angina, a normal resting ECG, and are able to exercise, with no difference in outcome. Thank you for agreeing to take part in the above study at Northwick Park Hospital, when you attended with chest pain 12 months ago. Please read the following questions carefully, and tick the box next to the answer which matches your health status over the past 12 months since your appointment:
(1) Have you had a heart attack (myocardial infarction) since your clinic appointment?
Yes A No A 
Appendix 2 Exercise testing protocols
Patients underwent treadmill exercise using the standard Bruce protocol. Endpoints were fatigue, severe ischaemia (severe chest pain, .2 mm horizontal or downsloping ST depression), severe hypertension (systolic BP . 220 mmHg), hypotension (systolic BP , 90 mmHg), pre-syncope, or significant arrhythmia. Patients who achieved a work-load of ≥9 METS or achieved 85% of target heart rate, without any symptoms, haemodynamic compromise, or ECG changes were considered to have a negative test. 14 Patients, who developed significant chest pain, hypotension, arrhythmia, or ≥1 mm planar or downsloping ST depression in two or more leads of the same territory, during exercise or in recovery, were considered to have a positive test. All other patients were considered to have an inconclusive test.
